In model 3 (adjusted covariates of age, gender, OASIS, CCI, SOFA score, ethnicity, weight, MBP, respiratory rate, HR, SpO2, temperature, WBC, hemoglobin, platelet, potassium, chloride, anion gap, creatinine, BUN, ALT, AST, MI, CLD, CHF, renal disease, liver disease, severe liver disease, malignant cancer, RRT use, and vasopressor use, ventilator use), the effect size increase by 4% (HR: 1.04, 95% CI 1.03–1.04) for every 1 unit increase in APAR. This evidence concerns the gene GPT and congestive heart failure.